McCarthy Claudia A, Vinh Antony, Callaway Jennifer K, Widdop Robert E
Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Stroke. 2009 Apr;40(4):1482-9. doi: 10.1161/STROKEAHA.108.531509. Epub 2009 Feb 26.
The angiotensin II type 2 receptor (AT(2)R) is implicated to be neuroprotective in stroke, although this premise has not been directly tested. Therefore, we have examined the neuroprotective effect of AT(2)R stimulation after intracerebroventricular administration of AT(2)R agonist CGP42112 in a conscious rat model of stroke.
Spontaneously hypertensive rats were treated with either CGP42112 (0.1 to 10 ng/kg/min intracerebroventricularly) alone or in combination with the AT(2)R antagonist PD123319 (36 ng/kg/min intracerebroventricularly) beginning 5 days before stroke induction. A focal reperfusion model of stroke was induced in conscious spontaneously hypertensive rats by administering endothelin-1 to the middle cerebral artery through a surgically implanted cannula. Behavioral tests were used to assess the severity of neurological deficit as a result of the ischemic event. Cortical and striatal infarct volumes were measured 72 hours poststroke.
Blood pressure was unaffected by treatments. CGP42112 dose-dependently reduced cortical infarct volume poststroke, and PD123319 abolished the neuroprotective effect of CGP42112. PD123319 had no effect on infarct volume alone. These results were consistent with the behavioral findings, indicating that CGP42112 reduced motor deficit on the ledged beam test at 72 hours poststroke and immunohistochemical analyses showing that CGP42112 increased neuronal survival and minimized the loss of AT(2)R expression in the infarcted region.
Based on infarct, behavioral, and immunohistochemical data, these results indicate that centrally administered CGP42112 exhibits a neuroprotective effect, which was independent of blood pressure. Thus, for the first time, we have shown that central AT(2)R stimulation is neuroprotective in a conscious rat model of stroke.
血管紧张素II 2型受体(AT(2)R)被认为在中风中具有神经保护作用,尽管这一前提尚未得到直接验证。因此,我们在清醒大鼠中风模型中,研究了脑室内注射AT(2)R激动剂CGP42112后AT(2)R刺激的神经保护作用。
自发性高血压大鼠在中风诱导前5天开始,单独给予CGP42112(脑室内注射剂量为0.1至10 ng/kg/分钟)或与AT(2)R拮抗剂PD123319(脑室内注射剂量为36 ng/kg/分钟)联合给药。通过手术植入的套管向清醒的自发性高血压大鼠大脑中动脉注射内皮素-1,诱导中风局灶性再灌注模型。行为测试用于评估缺血事件导致的神经功能缺损严重程度。中风后72小时测量皮质和纹状体梗死体积。
治疗对血压无影响。CGP42112剂量依赖性地减少了中风后的皮质梗死体积,而PD123319消除了CGP42112的神经保护作用。单独使用PD123319对梗死体积无影响。这些结果与行为学研究结果一致,表明CGP42112在中风后72小时的窄梁试验中减少了运动功能缺损,免疫组织化学分析显示CGP42112增加了神经元存活,并使梗死区域的AT(2)R表达损失最小化。
基于梗死、行为学和免疫组织化学数据,这些结果表明脑室内注射CGP42112具有神经保护作用,且与血压无关。因此,我们首次证明在清醒大鼠中风模型中,中枢AT(2)R刺激具有神经保护作用。